Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 1;7(44):71727-71736.
doi: 10.18632/oncotarget.12327.

Correlation of neuroendocrine features with prognosis of non-small cell lung cancer

Jianguo Feng  1   2 , Huaying Sheng  3 , Chihong Zhu  2 , Xiaoqian Qian  2 , Danying Wan  2 , Dan Su  1   2 , Xufeng Chen  4 , Liming Zhu  5
Affiliations

Correlation of neuroendocrine features with prognosis of non-small cell lung cancer

Jianguo Feng et al. Oncotarget. .

Abstract

The improvement in histological diagnostic tools, including neuroendocrine markers by immunohistochemistry (IHC), has led to increased recognition of non-small cell lung cancer (NSCLC) with neuroendocrine (NE) feature. However, little is known regarding the prevalence and clinical implications of NE feature in patients with NSCLC. In this study, we performed IHC in a tissue microarray containing 451 Chinese NSCLC cases, and analyzed correlation of the expression of neuroendocrine marker with pathological and clinical features of NSCLC. The result showed that NE feature in NSCLC was detectable in almost 30% of studied patients, and tumors with NE feature were significantly correlated with pathological classification, clinical stages and cell differentiation of NSCLC. Our data also revealed that NE feature indicated worse overall survival and disease free survival. Compared with mutant p53, NE markers showed more significance as for prognostic evaluation. Multi-factor COX analysis further suggested a potential clinical impact for NE feature as an independent indicator of poor prognosis for NSCLC patients.

Keywords: CD56; CgA; Syn; neuroendocrine; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

All authors declared no competing financial interests or other conflicts of interest related to this study.

Figures

Figure 1
Figure 1. Expression of CD56, CgA, Syn and mutatn p53 in NSCLC
Samples were stained by immunohistochemical method, and representative images of positive and negative staining were shown as indicated. Images were taken under microscope and magnified by 400 × fold.
Figure 2
Figure 2. Correlation of CD56, CgA, Syn, NE feature and mutant p53 with prognosis of NSCLC
Correlation of CD56, CgA, Syn, NE feature and mutant p53 with DFS and OS of NSCLC patients were analyzed by kaplan-meier method using Log rank statistics. p value < 0.05 indicating statistical significance.
Figure 3
Figure 3. Correlation of NE feature with prognosis of NSCLC
Correlation of NE feature with DFS and OS of NSCLC patients at same staging, in same group of patients with or without lymph-node metastasis, in same group of patients with adenocarcinoma or with squamous carcinoma, or in same group of patients with different grade of tumors were analyzed by kaplan-meier method using Log rank statistics. p value < 0.05 indicating statistical significance.
Figure 3
Figure 3. Correlation of NE feature with prognosis of NSCLC
Correlation of NE feature with DFS and OS of NSCLC patients at same staging, in same group of patients with or without lymph-node metastasis, in same group of patients with adenocarcinoma or with squamous carcinoma, or in same group of patients with different grade of tumors were analyzed by kaplan-meier method using Log rank statistics. p value < 0.05 indicating statistical significance.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. doi: 10.3322/caac.20073. - DOI - PubMed
    1. Chen W, Zhang S, Zou X. Estimation and projection of lung cancer incidence and mortality in China. [Article in Chinese] Zhongguo Fei Ai Za Zhi. 2010;13:488–93. doi: 10.3779/j.issn.1009-3419.2010.05.20. - DOI - PMC - PubMed
    1. Yang L, Li L, Chen Y, Parkin DM. Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China. [Article in Chinese] Zhongguo Fei Ai Za Zhi. 2005;8:274–8. doi: 10.3779/j.issn.1009-3419.2005.04.05. - DOI - PubMed
    1. Sheng H, Ying L, Zheng L, Zhang D, Zhu C, Wu J, Feng J, Su D. Down Expression of FBP1 Is a Negative Prognostic Factor for Non-Small-Cell Lung Cancer. Cancer Invest. 2015;33:197–204. doi: 10.3109/07357907.2015.1020385. - DOI - PubMed